Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Ischemic Brain Injury in Hyperhomocysteinemia

In: Cerebral Ischemia [Internet]. Brisbane (AU): Exon Publications; 2021 Nov 6. Chapter 5.
Affiliations
Free Books & Documents
Review

Ischemic Brain Injury in Hyperhomocysteinemia

Jan Lehotsky et al.
Free Books & Documents

Excerpt

Homocysteine is an intermediate product of methionine metabolism. Hyperhomocysteinemia can be caused by high intake of methionine, deficiency of vitamin B12, folate, or both. Hyperhomocysteinemia causes cardio- and cerebrovascular diseases, including ischemic stroke. Hyperhomocysteinemia-induced oxidative stress, inflammation, and endoplasmic reticulum stress play an important role in the pathogenesis of several neurodegenerative diseases. Pyramidal neurons of the hippocampus are sensitive to prolonged levels of homocysteine due to the absence of metabolization by transsulfuration as well as by folate- or B12-dependent remethylation. This chapter highlights the role of hyperhomocysteinemia in neurodegenerative changes following cerebral ischemia. An overview of how hyperhomocysteinemia by itself, or in combination with ischemia-reperfusion injury, exacerbates neurodegeneration is presented. The role of hyperhomocysteinemia in amyloid deposition and hyperphosphorylation of tau protein in the brain, along with plasma metabolic alterations in cerebral ischemia-reperfusion injury is reviewed. Prevention of hyperhomocysteinemia may have therapeutic implications in cerebral ischemic stroke and deserves investigation.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declare no potential conflicts of interest concerning research, authorship, and/or publication of this chapter.

References

    1. Lehotský J, Burda J, Danielisová V, Gottlieb M, Kaplán P, Sániová B. Ischemic tolerance: the mechanisms of neuroprotective strategy. Anat Rec. 2009;292:2002–2012. https://doi.org/10.1002/ar.20970 . - DOI - PubMed
    1. Kwon HM, Lee YS, Bae HJ, Kang DW. Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke. Stroke. 2014;45(3):871–3. https://doi.org/10.1161/STROKEAHA.113.004099 . - DOI - PubMed
    1. Petras M, Tatarkova Z, Kovalska M, Mokra D, Dobrota D, Lehotsky J, et al. Hyperhomocysteinemia as a risk factor for the neuronal system disorders. J Physiol Pharmacol. 2014;65:15–23. - PubMed
    1. Herrmann W, Obeid R. Homocysteine: a biomarker in neurodegenerative diseases. Clin Chem Lab Med. 2011;49:435–441. https://doi.org/10.1515/CCLM.2011.084 . - DOI - PubMed
    1. Lehotský J, Tóthová B, Kovalská M, Dobrota D, Beňová A, Kalenská D, et al. Role of Homocysteine in the Ischemic Stroke and Development of Ischemic Tolerance. Front. Neurosci. 2016;10:538. https://doi.org/10.3389/fnins.2016.00538 . - DOI - PMC - PubMed

LinkOut - more resources